Your session is about to expire
← Back to Search
Levoketoconazole for Cushing Syndrome (OPTICS Trial)
OPTICS Trial Summary
This trial is for people with a disease that causes their body to make too much of the hormone cortisol. The drug being tested is designed to treat this by reducing the amount of cortisol the body makes.
- Cushing Syndrome
- Cushing's Disease
OPTICS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowOPTICS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 84 Patients • NCT03277690OPTICS Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Have medical professionals tried this specific treatment before on patients?
"There is one ongoing global clinical trial for Levoketoconazole that started in 2019. This study, which is sponsored by Cortendo AB, has completed its Phase 3 drug approval stage. A total of 60 patients have been involved across 7 cities and 11 countries. 5 studies have been completed since 2019."
Are there other examples of Levoketoconazole being used in a medical capacity?
"Currently, there is 1 ongoing clinical trial involving Levoketoconazole. This active trial is in its third stage. Most of the research for Levoketoconazole takes place in Budapest and Ohio, but there are 30 different locations running these studies."
Does the FDA sanction Levoketoconazole for public usage?
"There is evidence from multiple sources that Levoketoconazole is safe for use, so it received a score of 3."
Share this study with friends
Copy Link
Messenger